September 27th 2022
Kim Blenman, PhD, MS, discussed the promising developments in cell-counting software for predicting pathologic complete response in breast cancer.
September 24th 2022
Long-Term Follow-Up Spotlights Ongoing Positive Outcomes With Selpercatinib in RET Fusion–Positive CancersJuly 2nd 2022
Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.
FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E+ Tumor-Agnostic IndicationJune 23rd 2022
Dabrafenib plus trametinib may now be used to treat patients with BRAF V600E–positive solid tumors who have no suitable alternative treatment options following its approval by the FDA.
Cobimetinib Plus Vemurafenib Produces Antitumor Activity in Patients With BRAF MutationsJune 7th 2022
Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.
Advanced Solid Tumors With High TMB in Both Tissue and Blood Experience Impressive ORR With Nivolumab/IpilimumabApril 11th 2022
Acceptable efficacy and safety were elicited in patients with advanced solid tumors and high tumor mutational burden detectable in both blood and tissue samples with nivolumab/ipilimumab therapy.
Artificial Intelligence–Based Whole Slide Scoring Accurately Identified Status for Several Key Breast Cancer MarkersDecember 10th 2021
Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms
Repotrectinib Granted Breakthrough Therapy Designation By FDA for Solid Tumors With NTRK Gene FusionOctober 6th 2021
Patients with solid tumors and an NTRK gene fusion who experienced progressive disease appear to derive benefit from repotrectinib, which received a breakthrough therapy designation from the FDA.
Pathogenic Variant Frequency in Late-Onset Breast Cancer May Inform Future Screening PracticesSeptember 5th 2021
Data collected from several large studies of women with breast cancer over the age of 65 years at diagnosis show how frequently certain known pathogenic variants occur in different patient subsets.
FDA Approves Oncomine Dx Target Test as a Companion Diagnostic for Ivosidenib in IDH1+ CholangiocarcinomaAugust 26th 2021
Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.
FDA Approves First Companion Diagnostic for Dostarlimab-gxly in dMMR Solid TumorsAugust 19th 2021
The VENTANA MMR RxDx Panel is the first FDA-approved companion diagnostic for identifying patients with DNA mismatch repair–deficient solid tumors who might benefit from treatment with dostarlimab-gxly.
Primary Prophylaxis With Biosimilar of Filgrastim Appears to be a Cost Effective Option for Individuals at Intermediate Risk of Febrile NeutropeniaAugust 19th 2021
Investigators theorize that a filgrastim-sndz biosimilar is an affordable option for patients across a number of tumor types who are undergoing curative intent treatment with chemotherapy and have an intermediate risk for experiencing febrile neutropenia.
Dostarlimab Gains New FDA-Approved Indication for Treatment of Mismatch Repair–Deficient TumorsAugust 17th 2021
Solid tumors with mismatch repair deficiency that have progressed on or after prior treatment and which have no suitable alternative therapy options may now be treated with dostarlimab following its approval by the FDA.
Profilin 1 Protein and Its Implications for CancersJuly 15th 2021
Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Post-Hoc Analysis of Pivotal Trial Demonstrates Safety of Selpercatinib in RET-Altered Advanced Solid TumorsApril 27th 2021
Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.
Zenocutuzumab Shows Ability to Inhibit NRG1 Fusion–Positive TumorsApril 14th 2021
Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.
Higher Cutoff by FoundationOne CDx for TMB May Determine Atezolizumab SuccessApril 13th 2021
In an analysis of a cohort of patients treated with atezolizumab in the myPathway trial, a tumor mutational burden cutoff of 16 mutations per megabase or higher was key for achieving durable responses in various solid tumors.
Reviewing Various Biomarker Settings for Patients with Prostate CancerDecember 4th 2020
The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.
NCI-MATCH Supports Using NGS to Triage Patients to Investigational TherapyOctober 21st 2020
Results from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, provided that a sufficiently large pool of agents is made available.